Asthma and COPD Drugs Market Expected to Reach $32.9 Billion by 2030
"Asthma and COPD drugs market by Disease and Medication Class: Global Opportunity Analysis and Industry Forecast, 2021-2030", the asthma and COPD drugs market size was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64% from 2021 to 2030.
Download Sample Report : https://www.alliedmarketresearch.com/request-sample/311
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the asthma and COPD drugs market as most hospitals are not operating due to COVID-19 and the ongoing lockdowns in many countries. The COVID-19 virus has serious and life-threatening impact on patients with respiratory disorders. However, a huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for the patient diagnosed with COVID-19, and this is expected to increase the diagnosis and treatment of respiratory diseases, which contributes in the market growth.
Asthma is respiratory condition marked by attacks of spasm in the bronchi of lungs, causing difficulty in breathing. It is usually connected to allergic reactions or other forms of hypersensitivity. COPD is a group of respiratory diseases, in which there is constriction of airways and difficulty or discomfort in breathing.
The asthma and COPD can be prevented and treated with drugs such as corticosteroids, short-acting beta agonists, and anticholinergic drugs. In the acute asthmatic attack, patient feels difficulty to breathe due to sudden narrowing of bronchi, generally due to allergens. In acute asthmatic attack, bronchodilators give quick relief and can be life saving for patients.
Key Market Players
Abbott Laboratories
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Glaxosmithkline Plc
Hoffmann-La Roche Ltd
Novartis AG
Organon
Sanofi
Teva Pharmaceutical Industries Ltd
Vectura Group Plc
Key Findings Of Study
On the basis of diseases, the asthma segment was the highest contributor to the market in 2020.
On the basis of medication class, combination drug segment dominated the market in 2020.
On the basis of region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
North America accounted for a majority of the global asthma and COPD drugs market share in 2020, and is anticipated to remain dominant during the forecast period. Asia-Pacific is anticipated to witness lucrative growth, owing to the increase in number of asthma and COPD patients.
Key Market Segments
BY DISEASES
Asthma
COPD
BY MEDICATION CLASS
Combination Drugs
Short Acting Beta Agonists (SABA)
Long Acting Beta Agonists (LABA)
Leukotriene Antagonists (LTA)
Anticholinergics
Others
Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/311
Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.
Asthma is respiratory condition marked by attacks of spasm in the bronchi of lungs, causing difficulty in breathing. It is usually connected to allergic reactions or other forms of hypersensitivity. COPD is a group of respiratory diseases, in which there is constriction of airways and difficulty or discomfort in breathing.
The asthma and COPD can be prevented and treated with drugs such as corticosteroids, short-acting beta agonists, and anticholinergic drugs. In the acute asthmatic attack, patient feels difficulty to breathe due to sudden narrowing of bronchi, generally due to allergens. In acute asthmatic attack, bronchodilators give quick relief and can be life saving for patients.
Key Market Players
Abbott Laboratories
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Glaxosmithkline Plc
Hoffmann-La Roche Ltd
Novartis AG
Organon
Sanofi
Teva Pharmaceutical Industries Ltd
Vectura Group Plc
Key Findings Of Study
On the basis of diseases, the asthma segment was the highest contributor to the market in 2020.
On the basis of medication class, combination drug segment dominated the market in 2020.
On the basis of region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
North America accounted for a majority of the global asthma and COPD drugs market share in 2020, and is anticipated to remain dominant during the forecast period. Asia-Pacific is anticipated to witness lucrative growth, owing to the increase in number of asthma and COPD patients.
Key Market Segments
BY DISEASES
Asthma
COPD
BY MEDICATION CLASS
Combination Drugs
Short Acting Beta Agonists (SABA)
Long Acting Beta Agonists (LABA)
Leukotriene Antagonists (LTA)
Anticholinergics
Others
Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/311
Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.
